Background
- Patients with hormone receptor-positive breast cancer (HR+BC)and pathogenic variants in BRCA1, BRCA2 or PALB2 (BRCA+) have several targeted therapy options including CDK4/6 inhibitors (CDK4/6i), and poly (ADP-ribose) polymerase inhibitors (PARPi).
- Little is known about the sequence of these targeted therapies
- Are there pathogenic variants between BRCA+ and their wildtypes?
- Specific Aims:
- To compare patients with hormone receptor-positive breast cancer and pathogenic variants in BRCA+ treated with CDK4/6i and/or PARPi
- To compare pathogenic variants in BRCA+ with their respective wildtypes in hormone receptor-positive breast cancer patients
- Compare low vs high tumor mutation burden for BRCA+ in hormone receptor-positive breast cancer patients